Drilldown: Medicines
Medicines > classes 
:
Anticonvulsant or
[[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]]
:
Anticonvulsant or
[[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]] Use the filters below to narrow your results.
generic:
Brivaracetam (1) ·
Budesonide (1) ·
Cannabidiol (1) ·
Cenobamate (1) ·
Clobazam (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fluticasone (1) ·
Fosphenytoin (1) ·
Lacosamide (1) ·
Mometasone furoate (1) ·
Perampanel (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Rufinamide (1) ·
Stiripentol (1) ·
Tiagabine (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Zonisamide (1)
brand:
Aptiom (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fintepla (1) ·
Flonase (intranasal, OTC); Flovent (inhaled, asthma); Cutivate (topical) (1) ·
Fycompa (1) ·
Gabitril (1) ·
Luminal (1) ·
Nasonex (intranasal), Asmanex (inhaled), Elocon (topical), Sinuva (sinus implant); with formoterol as Dulera (1) ·
Onfi (1) ·
Pulmicort (inhaled), Rhinocort (intranasal), Entocort EC and Uceris (enteric-coated oral for IBD), Symbicort (with formoterol) (1) ·
Sabril (1) ·
Vimpat (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
None (3) ·
AMPA receptor antagonist (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1)
uses:
None (19) ·
'"`UNIQ--vote-000001D9-QINU`"', '"`UNIQ--vote-000001DA-QINU`"', '"`UNIQ--vote-000001DB-QINU`"', '"`UNIQ--vote-000001DC-QINU`"' (1) ·
'"`UNIQ--vote-0000099F-QINU`"', '"`UNIQ--vote-000009A0-QINU`"', '"`UNIQ--vote-000009A1-QINU`"', '"`UNIQ--vote-000009A2-QINU`"', '"`UNIQ--vote-000009A3-QINU`"', '"`UNIQ--vote-000009A4-QINU`"' (1) ·
'"`UNIQ--vote-00000F98-QINU`"', '"`UNIQ--vote-00000F99-QINU`"', '"`UNIQ--vote-00000F9A-QINU`"', '"`UNIQ--vote-00000F9B-QINU`"' (1)
starting dose:
None (19) ·
ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID (1) ·
Inhaled (Flovent HFA) 88 mcg BID; intranasal (Flonase) 2 sprays/nostril daily; topical (Cutivate) 0.05% cream BID (1) ·
Intranasal Nasonex 2 sprays/nostril daily (50 mcg/spray); inhaled Asmanex 220 mcg DPI 1-2 inhalations daily/BID; topical Elocon 0.1% cream daily (1)
preparations:
None (19) ·
Inhaled MDI 44/110/220 mcg per actuation; DPI (Diskus) 50/100/250 mcg; nasal spray 50 mcg/actuation; cream/ointment 0.005%, 0.05% (1) ·
Nasonex 50 mcg/actuation intranasal; Asmanex HFA MDI 100/200 mcg; Asmanex Twisthaler DPI 110/220 mcg; Elocon 0.1% cream/ointment/lotion; Sinuva sinus implant; Dulera (with formoterol) (1) ·
Pulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (19) ·
<1% oral (extensive first-pass via CYP3A4); ~30% inhaled lung deposition'"`UNIQ--ref-000001DE-QINU`"' (1) ·
Intranasal: <1% systemic; inhaled lung deposition with extensive first-pass clearance'"`UNIQ--ref-00000F9D-QINU`"' (1) ·
~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"' (1)
pregnancy:
None (19) ·
Inhaled and intranasal generally considered safe; widely used in asthma in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Intranasal long considered acceptable; widely used in obstetric rhinitis.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Long the preferred ICS in pregnancy (Pulmicort) due to the most pregnancy data among the class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
Showing below up to 22 results in range #1 to #22.